- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04744116
Tilsetning av navlestrengsblodvevsavledede mesenkymale stromaceller til Ruxolitinib for behandling av steroid-refraktær akutt graft versus vertssykdom
En randomisert kontrollert pilotstudie av to doser av navlestrengsblodvev-avledede mesenkymale stromaceller kombinert med ruxolitinib versus ruxolitinib alene for terapi av steroid-refraktær akutt graft versus vertssykdom
This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM 1: Patients receive ruxolitinib orally (PO) twice daily (BID) for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
ARM 2: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs intravenously (IV) for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
ARM 3: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
After completion of study treatment, patients are followed up on day 28 and then for up to 6 months.
Studietype
Registrering (Antatt)
Fase
- Tidlig fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Partow Kebriaei, MD
- Telefonnummer: 713-745-0663
- E-post: pkebriae@mdanderson.org
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- M D Anderson Cancer Center
-
Ta kontakt med:
- Partow Kebriaei, MD
- Telefonnummer: 713-745-0663
- E-post: pkebriae@mdanderson.org
-
Hovedetterforsker:
- Partow Kebriaei, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants between the ages of 12 years and 80 years (inclusive).
- Steroid refractory grades II-IV acute GVHD of the Lower GI tract or Liver (including those developing these manifestations after previous acute GVHD of skin) secondary to allogeneic HCT or donor lymphocyte infusion. (Grading, see Appendix I) GVHD with: No improvement after treatment with methylprednisolone at ≥ 2.0 mg/kg/day or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids. Participants must have had a biopsy that suggests GVHD; a repeat biopsy to enroll on the study is not necessary.
- Karnofsky/Lansky Performance score of at least 30 at the time of study entry.
- Participants who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception
- Participants (or legal representative where appropriate) must be capable of providing written informed consent, and assent if indicated.
Exclusion Criteria:
- De novo chronic GVHD
- Isolated acute GVHD of skin
- Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy.
- Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib.
- Participants with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- Adult and pediatric patients with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
- Participants with significant supplemental oxygen requirement defined as >6 L oxygen by nasal cannula.
- Participants with known allergy to bovine or porcine products.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm 1 (ruxolitinib)
Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued. |
Given PO
Andre navn:
|
|
Eksperimentell: Arm 2 (ruxolitinib, lower dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses. |
Given PO
Andre navn:
Given ds-MSCs IV
Andre navn:
|
|
Eksperimentell: Arm 3 (ruxolitinib, higher dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses. |
Given PO
Andre navn:
Given ds-MSCs IV
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Død uansett årsak
Tidsramme: Innen 28 dager fra starten av aktiv studiebehandling
|
Innen 28 dager fra starten av aktiv studiebehandling
|
|
|
Forekomst av uønskede hendelser
Tidsramme: Innen 28 dager fra starten av aktiv studiebehandling
|
Innen 28 dager fra starten av aktiv studiebehandling
|
|
|
Response
Tidsramme: At day 28 from start of therapy on study
|
Will compare the patient's 28-day graft versus host disease (GVHD) status to the patient's baseline GVHD status when steroid refractory acute GVHD was diagnosed. |
At day 28 from start of therapy on study
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Forekomst av fullstendig respons for hvert organ
Tidsramme: Inntil 6 måneder
|
Inntil 6 måneder
|
|
|
Forekomst av svært god delrespons for hvert organ
Tidsramme: Inntil 6 måneder
|
Inntil 6 måneder
|
|
|
Forekomst av delvis respons for hvert organ
Tidsramme: Inntil 6 måneder
|
Inntil 6 måneder
|
|
|
Holdbarhet av organrespons
Tidsramme: Inntil 6 måneder
|
Inntil 6 måneder
|
|
|
Kumulativ forekomst av ikke-tilbakefallsdødelighet (NRM)
Tidsramme: 6 måneder etter behandling
|
6 måneder etter behandling
|
|
|
Kumulativ forekomst av tilbakefall/progresjon av primærsykdommen
Tidsramme: Ved 6 måneder
|
Ved 6 måneder
|
|
|
Total overlevelse
Tidsramme: Fra innmelding til død uansett årsak, vurdert til 6 måneder
|
Fra innmelding til død uansett årsak, vurdert til 6 måneder
|
|
|
Sykdomsfri overlevelse
Tidsramme: Fra innmelding til død av enhver årsak eller tilbakefall/progresjon av primærsykdommen, vurdert etter 6 måneder
|
Fra innmelding til død av enhver årsak eller tilbakefall/progresjon av primærsykdommen, vurdert etter 6 måneder
|
|
|
Forekomst av enhver grad av cytokinfrigjøring
Tidsramme: Inntil 28 dager etter fullføring av siste MSC-infusjonsstudiemedisin
|
Inntil 28 dager etter fullføring av siste MSC-infusjonsstudiemedisin
|
|
|
Forekomst av infusjonstoksisitet
Tidsramme: Innen 24 timer etter hver navlestrengsblod-MSC-infusjon
|
Innen 24 timer etter hver navlestrengsblod-MSC-infusjon
|
|
|
Graft versus host disease status
Tidsramme: At days 7, 14, 21 and 28 post treatment
|
Will assess complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD). |
At days 7, 14, 21 and 28 post treatment
|
|
Proportion of response
Tidsramme: At days 7, 14, 21 and 28 post treatment
|
Will assess proportion of patients with CR, PR, VGPR, and no-response (NR). The event NR is defined as stable disease, mixed response, disease progression, OR initiation of additional systemic (second-line) GVHD therapies. |
At days 7, 14, 21 and 28 post treatment
|
|
Time to complete response
Tidsramme: Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Time to very good partial response
Tidsramme: Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Time to partial response
Tidsramme: Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Graft versus host disease-free survival
Tidsramme: At 6 months
|
Patients alive, free of active acute or chronic GVHD, and without other systemic agents (or escalation of steroids to >= 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) added for treatment of GVHD will be considered successes for this endpoint |
At 6 months
|
|
Incidence of chronic graft versus host disease
Tidsramme: At 6 months after first mesenchymal stromal cells (MSC) infusion
|
Chronic GVHD is defined per National Institutes of Health Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint. Organ involvement and maximum severity will also be described at six months. |
At 6 months after first mesenchymal stromal cells (MSC) infusion
|
|
Incidence of systemic infections
Tidsramme: 28 days after last study drug
|
The incidence of grade 2 to 3 systemic infections occurring from study treatment until 28 days after last study drug will be described using standard Common Terminology Criteria for Adverse Events (CTCAE) criteria. Infections will be recorded by site of disease, date of onset, and severity. |
28 days after last study drug
|
|
Incidence of toxicities
Tidsramme: Up to 28 days after completing last MSC infusion study drug
|
The incidence of grade 3-5 treatment-emergent adverse events (per CTCAE version 5.0) that occur through 28 days after completing last MSC infusion study drug will be described. |
Up to 28 days after completing last MSC infusion study drug
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cytokine biomarker analysis (optional)
Tidsramme: Up to 6 months
|
Will use cytokine biomarker assays to predict response to therapy. |
Up to 6 months
|
|
Fecal samples analysis (optional)
Tidsramme: Up to 6 months
|
Will use fecal samples to assess microbiome and potential predictor for response to therapy. |
Up to 6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Partow Kebriaei, MD, M.D. Anderson Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2019-1122
- 2019-1122 (Annen identifikator: M D Anderson Cancer Center)
- NCI-2020-13889 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- P01CA148600 (U.S. NIH-stipend/kontrakt)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .